You cannot add another "Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma" to your cart. View cart

Article: The RANK ligand inhibitor denosumab as novel therapeutic agent in the spectrum of cancer bone disease

€2.42

SKU: product-article-11135 Category: General

Description
Reviews (0)

Description

The RANK ligand inhibitor denosumab as novel therapeutic agent in the spectrum of cancer bone disease

Reviews

There are no reviews yet.

Be the first to review “Article: The RANK ligand inhibitor denosumab as novel therapeutic agent in the spectrum of cancer bone disease”

Top

Article: The RANK ligand inhibitor denosumab as novel therapeutic agent in the spectrum of cancer bone disease

Description

Reviews

Related products

Article: INTRODUCTION

Article: Highlights in melanoma

1 year subscription print edition of the Belgian Journal of Hematology (BJH)

Article: Highlights in digestive oncology